G1 Therapeutics, Inc.G1 Therapeutics, Inc.G1 Therapeutics, Inc.

G1 Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪244.29 M‬USD
−0.93USD
‪−47.97 M‬USD
‪82.51 M‬USD
‪42.38 M‬
Beta (1Y)
1.86

About G1 Therapeutics, Inc.

CEO
Jack Bailey
Headquarters
Research Triangle Park
Employees (FY)
100
Founded
2008
ISIN
US3621LQ1099
FIGI
BBG005F1DK91
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of GTHX is 4.48 USD — it has decreased by 4.27% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange G1 Therapeutics, Inc. stocks are traded under the ticker GTHX.
G1 Therapeutics, Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for G1 Therapeutics, Inc. has a max estimate of 12.00 USD and a min estimate of 5.00 USD.
GTHX earnings for the last quarter are −0.35 USD whereas the estimation was −0.34 USD which accounts for −2.74% surprise. Estimated earnings for the next quarter are −0.28 USD. See more details about G1 Therapeutics, Inc. earnings.
G1 Therapeutics, Inc. revenue for the last quarter amounts to ‪12.30 M‬ USD despite the estimated figure of ‪14.24 M‬ USD. In the next quarter revenue is expected to reach ‪13.08 M‬ USD.
Yes, you can track G1 Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, GTHX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade G1 Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
GTHX reached its all-time high on Sep 11, 2018 with the price of 69.57 USD, and its all-time low was 1.08 USD and was reached on Oct 9, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 12, 2024, the company has 100.00 employees. See our rating of the largest employees — is G1 Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. G1 Therapeutics, Inc. EBITDA is ‪−39.01 M‬ USD, and current EBITDA margin is −47.28%. See more stats in G1 Therapeutics, Inc. financial statements.